lerodalcibep for Heterozygous familial hypercholesterolemia

Inclusion criteria

• {"criterion_text":"- 1. Provision of written and signed informed consent/assent prior to any study-specific procedure\n- 10. Male patients must refrain from sperm donation until 90 days following the last dose of study drug\n- 2. Male or female, 6 to 17 years of age (defined as from 6 to less than 18 years of age), at the first Screening Visit\n- 3. Weight of more than 18 kg (40 lbs) and BMI more than 17 and less than 42 kg/m2\n- 4. Diagnosis of definite or probable Heterozygous Familial Hypercholesterolemia (HeFH) based on clinical criteria (SB Register, MEDPED or DLCN criteria) or genotyping and at the defined eligibility visit (Screening Visit or post washout/stabilization); a calculated LDL-C (Friedewald) equal or above 130 mg/dL and TG below 400 mg/dL while on stable lipid-lowering oral drug therapy (eg, maximally tolerated statin with or without ezetimibe); Note: Patients unable to tolerate approved doses of a statin may take lower than approved doses and less frequently than daily as long as the dose and dosing frequency is consistent per the Investigator's judgment. Patients with documented intolerance to statins may also participate.\n- 5. On a stable diet and lipid-lowering oral therapies (statins, ezetimibe, bile-acid sequestrants) or combinations thereof for at least 6 weeks (excluded oral lipid-lowering agents include mipomersen, lomitapide, and gemfibrozil)\n- 6. Patients on a PCSK9 mAb must undergo a washout period of ≥8 weeks after the last dose. For patients who have received an siRNA PCSK9 inhibitor the washout period is 360 days post last dose\n- 7. Females of childbearing potential must be using a highly effective form of contraception as specified in the study protocol during the study and until 60 days after last dose of study drug if sexually active and have negative urine pregnancy test during the trial and at the last Screening Visit\n- 8. Females of child bearing potential are not permitted to donate oocytes during exposure to the IMP or for 90 days after the last dose of study drug\n- 9. Male patients will either be surgically sterile or agree to use the following forms of contraception until 90 days after the last dose of study drug: male or female condom with spermicide and a female partner who is sterile or who agrees to use the following contraceptives: diaphragm or cervical cap with spermicide; or IUD, oral, implantable, or injectable contraceptives"}

Exclusion criteria

• {"criterion_text":"- 1. Use of prohibited oral lipid-lowering agents mipomersen or lomitapide within 6 months of screening or gemfibrozil within 6 weeks of the Screening Visit\n- 10. Uncontrolled serious cardiac arrhythmia (sustained ventricular tachycardia, frequent non sustained ventricular tachycardia, any ventricular fibrillation episode, wide-complex tachycardia, atrial fibrillation with rapid ventricular response, and severe second-degree or third degree atrioventricular block), myocardial infarction (MI), unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, placement of implantable cardioverter defibrillator or biventricular pacemaker, aortic valve surgery, or stroke within 3 months prior to enrollment (the day patient signs the informed consent/assent and first procedure is performed)\n- 11. Planned cardiac surgery or revascularization\n- 12. New York Heart Association III-IV heart failure; or patients with last documented left ventricular ejection fraction <30% by standard of care assessments (eg, echocardiography, cardiac magnetic resonance imaging, nuclear imaging, computed tomography angiography, or angiography with ventriculogram), within 12 months\n- 13. Uncontrolled hypertension defined as on treatment diastolic or systolic BP ≥95th percentile for age and sex\n- 14. Enrolled in another investigational device or drug study, or less than 30 days or 5 half-lives since ending another investigational device or drug study(ies), or receiving other investigational agent(s); such as PCSK9 or ANGPTL3 or Lp(a) siRNA or locked nucleic acid reducing agents within 12 months of the Screening Visit\n- 15. Unexplained CK >5 × ULN, unless related to exercise or unusual activity in which case 1 repeat test is allowed\n- 16. Patients who cannot be available for Protocol-required study visits or procedures, to the best of the patient's and Investigator's knowledge\n- 17. A history, within 6 months prior to screening, of prescription drug abuse, illicit drug use, or alcohol abuse according to medical history\n- 18. Donated or lost a significant volume (>500 mL) of blood or plasma within 30 days prior to Day 1\n- 19. Had a blood transfusion within 4 weeks of randomization or known diagnosis of human immunodeficiency virus\n- 2. LDL or plasma apheresis within 2 months prior to Day 1\n- 20. Previous treatment with lerodalcibep or any adnectin product\n- 21. Have any other finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study\n- 22. An employee or family member of the Investigator or study site personnel\n- 3. Documented history of Homozygous Familial Hypercholesterolemia (HoFH) defined as clinical and/or genetic with true HoFH (ie, identical pathogenic variants), compound heterozygous (ie, 2 different pathogenic LDLR variants) or combined heterozygous (2 different pathogenic FH variants such as LDLR plus ApoB or LDLR plus PCSK9 gain-of function)\n- 4. History of any prior or active clinical condition or acute and/or unstable systemic disease compromising patient inclusion, at the discretion of the Investigator, including but not limited to clinically significant pulmonary, hematologic, gastrointestinal, endocrine (excluding diabetes), immunologic, dermatologic, neurologic, or psychiatric disease, which in the Investigator's opinion, would not be suitable for the study from a patient safety consideration or could interfere with the results of the study\n- 5. Females of childbearing potential who are sexually active, not using or unwilling to use a highly effective form of contraception as specified in the study protocol during the study and until 60 days after last dose of study drug, pregnant or breastfeeding, or who have a positive urine pregnancy test at the last Screening Visit\n- 6. Moderate to severe renal dysfunction, defined as an estimated glomerular filtration rate <30 mL/min/1.73m2 at the Screening Visit\n- 7. Active liver disease or hepatic dysfunction (eg, cirrhosis, alcoholic liver disease, known hepatitis B or hepatitis C, autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, and/or AST or ALT >2.5 × the ULN based on age as determined by central laboratory analysis at screening (tests that result in ALT or AST up to 3 × ULN may have 1 repeat test to confirm eligibility during the Screening Period)\n- 8. Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal (LLN) or >1.5 × ULN, respectively, at the Screening Visit. If TSH is above/below these cut-off points, the patient can enter if the free triiodothyronine (FT3) is within the reference range. If controlled, then treatment should be stable for at least 3 months prior to the Screening Visit\n- 9. Uncontrolled Type 1 or Type 2 diabetes mellitus (defined as fasting glucose above 200 mg/dL and HbA1c of above 9%)"}

Primary endpoints

• {"endpoint_text":"- The percent change from baseline compared to placebo in LDL-C level (by preparative ultracentrifugation) at Week 24","definition_or_measurement_approach":"Percent change from baseline in LDL-C measured by preparative ultracentrifugation at Week 24 compared to placebo."}

Secondary endpoints

• {"endpoint_text":"- 1. Percent change in: o LDL-C level at Week 24 (by Hopkins formula and Friedewald); o LDL-C level at Weeks 12, 22 and the mean of Weeks 22 and 24 by Friedewald and Hopkins formula and LDL-C level at Week 24 by preparative ultracentrifugation","definition_or_measurement_approach":"Percent change in LDL-C at specified weeks measured by Hopkins and Friedewald formulas and by preparative ultracentrifugation at Week 24."}
• {"endpoint_text":"- 2. Absolute and percent change (where not assessed prior) from baseline in LDL-C level by Friedewald and Hopkins formulas at all visits (Weeks 4, 8, 12, 16, 20, 22, and 24)","definition_or_measurement_approach":"Absolute and percent change from baseline in LDL-C using Friedewald and Hopkins formulas at listed visits."}
• {"endpoint_text":"- 3. Serum unbound (free) PCSK9 and PK concentrations in lerodalcibep patients at Day 1, Week 12, and Weeks 22 and 24. Other visits including Weeks 4, 8, 12, 16, and 20 will be measured in response to ADAs in lerodalcibep patients. Samples from placebo patients will be stored","definition_or_measurement_approach":"Measure serum unbound PCSK9 and pharmacokinetic (PK) concentrations at specified timepoints; additional sampling may occur in response to ADAs; placebo samples stored."}
• {"endpoint_text":"- 4. Percentage of patients achieving current pediatric guidelines (EAS Consensus Panel 2015 target LDL-C < 3.5 mmol/L)","definition_or_measurement_approach":"Proportion of patients with LDL-C < 3.5 mmol/L per EAS pediatric guideline at specified assessments."}
• {"endpoint_text":"- 5. Growth and development including changes in height, weight, BMI, Tanner staging, and serum hormone levels (eg, estradiol, testosterone, dehydroepiandrosterone, follicle-stimulating hormone [FSH], luteinizing hormone, adrenocorticotropic hormone, and cortisol)","definition_or_measurement_approach":"Assessment of growth and developmental measures (height, weight, BMI, Tanner stage) and serum endocrine tests at protocol-specified visits."}
• {"endpoint_text":"- 6. Absolute and percent change from baseline in TC, HDL-C, non–HDL-C, VLDL-C, and TG at all visits (Weeks 4, 8, 12, 16, 20, 22, and 24)","definition_or_measurement_approach":"Laboratory measurement of lipid panel components at specified visits and calculation of absolute and percent change from baseline."}
• {"endpoint_text":"- 7. Absolute and percent change from baseline in ApoB and Lp(a) serum concentrations to Weeks 12, 22 and 24","definition_or_measurement_approach":"Measure ApoB and lipoprotein(a) at specified weeks and report absolute and percent change from baseline."}
• {"endpoint_text":"- 8. ADAs will be measured at Day 1 and Weeks 12 and 24/Early Termination (ET) in lerodalcibep patients. Measurements at other visits, including Weeks 4, 8, 16, and 20, may occur if ADAs are detected at Week 24/ET in lerodalcibep patients.","definition_or_measurement_approach":"Assessment of anti-drug antibodies at specified timepoints; additional measurements conditional on ADA detection."}
• {"endpoint_text":"- 9. The PK concentration for lerodalcibep and total serum PCSK9 will be measured at Weeks 12, 22 and Week 24/ET in lerodalcibep patients. Total serum PCSK9 will also be measured at Day 1. Other visits including Weeks 4, 8, 16, and 20 may be measured to support the population PK plan or the presence of ADAs in lerodalcibep patients.","definition_or_measurement_approach":"Pharmacokinetic sampling at specified timepoints for lerodalcibep and total serum PCSK9; additional sampling may support population PK or ADA findings."}
• {"endpoint_text":"- 10. Safety endpoints are AEs, including the frequency of AEs, SAEs, SARs and AEs leading to treatment discontinuation, cardiovascular events and all-cause mortality; safety laboratory parameters (chemistry, hematology, coagulation, and urinalysis), with particular attention to hepatic (eg alanine transaminase/aspartate transaminase, total bilirubin, alkaline phosphatase), fasting glucose and HbA1c and skeletal muscle (ie creatine kinase) toxicities; 12-lead ECGs; ISRs; phys exam and vital signs","definition_or_measurement_approach":"Standard safety monitoring including AE/SAE reporting, laboratory tests, ECGs, injection site reactions, physical exams and vital signs at protocol-specified visits."}

Norway

Earliest CTIS Part Ii Submission Date

24-04-2026

Latest Decision Or Authorization Date

13-05-2026

Processing Time Days

19

Number Of Sites

1

Number Of Participants

5

Primary sponsor

Full Name

LIB Therapeutics Inc.

Organisation Type

Pharmaceutical company

Country Of Registered Address

United States

Contract research organisations

Name

Medpace Finland Oy

Responsibilities

sponsorDuties codes: 1,10,12,3,4,5,6,7,8

Third parties

• {"country":"Finland","full_name":"Medpace Finland Oy","duties_or_roles":"sponsorDuties codes: 1,10,12,3,4,5,6,7,8","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Arup Laboratories Inc.","duties_or_roles":"sponsorDuties codes: 4","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"United States","full_name":"Biologics Development Services LLC","duties_or_roles":"sponsorDuties codes: 15 (Immunogenicity)","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"GB HealthWatch","duties_or_roles":"sponsorDuties codes: 4","organisation_type":"Health care"}